|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
intramuscular injection
|
|
gptkbp:approves
|
children under 12
December 2021
COVID-19 prevention
|
|
gptkbp:associated_with
|
reduced hospitalization rates
reduced transmission risk
reduced severe disease rates
|
|
gptkbp:available_in
|
vials
|
|
gptkbp:can_be_combined_with
|
other COVID-19 therapies
|
|
gptkbp:clinical_trial
|
Phase 3
pre-exposure prophylaxis
NCT04625725
NCT04797821
|
|
gptkbp:clinical_use
|
prophylactic treatment
|
|
gptkbp:contains
|
gptkb:cilgavimab
gptkb:tixagevimab
|
|
gptkbp:contraindication
|
history of severe allergic reactions
|
|
gptkbp:developed_by
|
gptkb:Astra_Zeneca
|
|
gptkbp:dosage_form
|
300 mg
|
|
gptkbp:frequency
|
every 6 months
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Evusheld
|
|
gptkbp:influenced_by
|
emerging variants of concern
|
|
gptkbp:informed_consent_required
|
before administration
|
|
gptkbp:invention
|
gptkb:Astra_Zeneca
|
|
gptkbp:is_compared_to
|
placebo
|
|
gptkbp:is_considered
|
post-exposure prophylaxis
|
|
gptkbp:is_effective_against
|
Omicron variant
over 80% in preventing symptomatic COVID-19
|
|
gptkbp:is_recommended_by
|
gptkb:CDC
gptkb:WHO
|
|
gptkbp:is_studied_for
|
long-term immunity
|
|
gptkbp:is_studied_in
|
immunocompromised populations
|
|
gptkbp:is_subject_to
|
regulatory review
|
|
gptkbp:marketed_as
|
gptkb:brand
|
|
gptkbp:mechanism_of_action
|
neutralizes SARS-Co V-2
|
|
gptkbp:not_substituted_for
|
vaccination
|
|
gptkbp:part_of
|
COVID-19 vaccination strategy
COVID-19 treatment guidelines
public health response to COVID-19
|
|
gptkbp:provides_guidance_on
|
updated regularly
|
|
gptkbp:received_emergency_use_authorization
|
gptkb:FDA
|
|
gptkbp:release_region
|
multiple countries globally
|
|
gptkbp:requires
|
medical supervision
cold chain logistics
|
|
gptkbp:research_published_in
|
gptkb:The_New_England_Journal_of_Medicine
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
allergic reactions
injection site reactions
|
|
gptkbp:storage
|
2 to 8 degrees Celsius
|
|
gptkbp:suitable_for
|
active COVID-19 infection
|
|
gptkbp:target_audience
|
adults and adolescents
|
|
gptkbp:used_in
|
clinical settings
immunocompromised patients
|
|
gptkbp:bfsParent
|
gptkb:Astra_Zeneca's_monoclonal_antibodies
|
|
gptkbp:bfsLayer
|
5
|